SPRB

Business Context and Reporting Period

Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Spruce is a late-stage biopharmaceutical company focused on developing therapies for neurological disorders. Its primary asset is tralesinidase alfa enzyme replacement therapy ("TA-ERT") for Sanfilippo Syndrome Type B (MPS IIIB), which has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. The company has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $1.8 million compared to Q1 2025, primarily driven by a $3.3 million decrease in Research and Development (R&D) expenses. This reduction was due to lower acquisition-related costs and the discontinuation of the tildacerfont CAH development program, partially offset by increased TA-ERT manufacturing expenses.
• Debt Financing: The company entered into a new Loan and Security Agreement with Avenue Capital Management in January 2026. As of March 31, 2026, $15.0 million (Tranche 1) was funded. This resulted in $0.7 million in interest expense and the recognition of a $3.9 million warrant liability.
• Liquidity Improvement: Cash and cash equivalents increased by approximately $28.5 million from the prior year period, driven by the new debt financing and a $2.6 million collection related to the Allievex bankruptcy proceedings.
• Stock Structure: Financial statements reflect a 1-for-75 reverse stock split effected in August 2025, which restored Nasdaq listing compliance.

Guidance, Outlook, and Risks

• Regulatory Outlook: Management intends to submit a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026, seeking accelerated approval based on CSF HS-NRE as a surrogate endpoint. Commercial launch is targeted for mid-2027 if approved.
• Liquidity Position: As of March 31, 2026, the company held $54.1 million in cash. Management believes this, combined with net proceeds from a subsequent April 2026 public offering (gross proceeds ~$69.0 million), is sufficient to fund operations for at least 12 months.
• Capital Needs: The company anticipates continuing to incur significant net losses. It will require substantial additional financing to complete clinical development, regulatory filings, and commercialization. Future funding may come from equity offerings, debt, or collaborations.
• Key Risks:
  • Regulatory Approval: Failure to demonstrate that CSF HS-NRE is a reasonably likely surrogate endpoint could delay or prevent accelerated approval.
  • Financing: Inability to raise additional capital could force delays or elimination of product development programs.
  • Intellectual Property: The company relies on licensed IP (e.g., from BioMarin and HBM Alpha Therapeutics). A recent European Patent Office decision revoked a key patent (EP '233), though an appeal is pending.
  • Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trial conduct.

Investor Verification Checklist

• BLA Submission Timeline: Verify the company's ability to meet the Q4 2026 BLA submission target and the FDA's acceptance of the proposed surrogate endpoint.
• Debt Covenants: Review the Avenue Loan Agreement covenants, specifically the milestone requirements for Tranche 2 ($10M) and Tranche 3 ($15M) funding.
• Patent Status: Monitor the outcome of the appeal regarding the revoked European Patent No. 3,784,233 and its impact on the company's IP portfolio.
• Cash Burn Rate: Assess the sustainability of the current cash position ($54.1M) against projected R&D and G&A expenses for the remainder of 2026.
• April 2026 Offering: Confirm the net proceeds and dilution impact of the public offering closed in April 2026 (subsequent to the reporting period).